RedHill Biopharma Ltd.

RedHill Biopharma Ltd. announced its Annual General Meeting of Shareholders to be held on July 28, 2026. Key agenda items include the re-appointment of auditors, the re-election of Mr. Rick D. Scruggs and Dr. Shmuel Cabilly to the Board of Directors for three-year terms, and the approval of Mr. Dror Ben-Asher to serve concurrently as Chairman of the Board and Chief Executive Officer for three years. Shareholders will also review the company's financial statements for the fiscal year ended December 31, 2025.

RedHill Biopharma Ltd. has entered into a private placement agreement with an accredited investor to issue 8,571,429 American Depositary Shares (ADSs) and accompanying Series A-1 and Series A-2 warrants. The combined purchase price is $0.70 per ADS and warrants. The company expects to raise approximately $6 million in gross proceeds from this offering, with a potential additional $13.4 million if all warrants are exercised. H.C. Wainwright & Co. acted as the exclusive placement agent.

RedHill Biopharma Ltd. announced its Annual General Meeting of Shareholders will be held on July 28, 2026, in Tel-Aviv, Israel. Key proposals include the re-appointment of Kesselman & Kesselman as auditors, the re-election of Mr. Rick D. Scruggs and Dr. Shmuel Cabilly to the Board of Directors, and the approval of Mr. Dror Ben-Asher's engagement as Chairman and CEO. Shareholders will also review the financial statements for the fiscal year ended December 31, 2025.

RedHill Biopharma Ltd. announced a private placement to raise up to $19.4 million. The company expects to receive approximately $6 million upfront from the sale of American Depositary Shares (ADSs) and accompanying warrants, with an additional potential $13.4 million if the Series A-1 and Series A-2 warrants are fully exercised. The proceeds are intended to support a potential strategic product acquisition, working capital, research and development, and general corporate purposes.

RedHill Biopharma Ltd. announced that its investigational drug, opaganib, has received Rare Pediatric Disease (RPD) designation from the U.S. Food and Drug Administration (FDA) for the treatment of neuroblastoma. This new designation complements opaganib's existing Orphan Drug Designation for neuroblastoma, offering potential benefits such as a Priority Review Voucher, accelerated development and review times, FDA fee waivers, tax credits, and seven years of marketing exclusivity if approved. The company highlighted new preclinical data presented at the 2026 AACR Annual Meeting, which showed positive effects of opaganib as a potential add-on therapy in models of neuroblastoma and triple-negative breast cancer, with the neuroblastoma market projected to reach $3.5 billion by 2032.

RedHill Biopharma Ltd. has initiated recognition and enforcement proceedings in Korea for an $10.9 million New York Supreme Court final judgment against Kukbo Co. Ltd. The judgment, which includes approximately $8.9 million for the principal award and $1.95 million for legal fees and expenses, became final in November 2025 and March 2026, respectively, with no further appeals possible. RedHill had previously secured a Korean court attachment against Kukbo to prevent asset disposal, and now awaits Kukbo's response in the Korean proceedings.

RedHill Biopharma is actively discussing collaborations, including with the WHO's SOLIDARITY CORE clinical trial platform, to advance its investigational oral drug opaganib for Ebola virus disease (EVD). Opaganib, a host-directed SPHK2 inhibitor, has shown a 70.2% mortality reduction in a Phase 3 COVID-19 trial when added to standard care and demonstrated preclinical EVD activity, including inhibition in human macrophages and increased survival in one animal model. The company highlights opaganib's dual mechanism of action against EVD, its oral administration, and ease of storage as crucial for addressing the current Bundibugyo ebolavirus outbreak.

RedHill Biopharma Ltd. announced it filed a prospectus supplement to increase the maximum aggregate offering amount of its American Depositary Shares (ADSs). These ADSs, each representing 10,000 ordinary shares, are offered under an At The Market Offering Agreement with H.C. Wainwright & Co., LLC, originally entered into on February 3, 2025.

RedHill Biopharma announced new in vitro data showing its next-generation drug, RHB-204, has comparable Mycobacterium avium subspecies paratuberculosis (MAP) killing efficacy to RHB-104 for Crohn's disease. This was achieved with lower doses of active ingredients, suggesting reduced toxicity and side effects. RHB-104 previously showed 64% greater efficacy in a Phase 3 study. A Phase 2 study for RHB-204 in MAP-positive CD patients is planned, with non-dilutive funding being pursued, highlighting significant market potential and existing regulatory designations.

RedHill Biopharma reported its full-year 2025 financial results, ending the year with positive equity of $4.3 million, a significant turnaround from a $4.7 million capital deficiency in 2024. The company highlighted strategic transactions, including the formation of Talicia Holdings Inc. and a co-commercialization partnership with Cumberland Pharmaceuticals, and the licensing of RHB-102 (Bekinda) to Hyloris for up to $60 million in potential milestones. RedHill also advanced its R&D pipeline for RHB-204 in Crohn's disease and opaganib in oncology, and secured a $10.5 million court ruling against Kukbo Co. Ltd.